New Zealand markets closed

BeiGene, Ltd. (BGNE)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
186.94+3.81 (+2.08%)
At close: 04:00PM EST
186.94 0.00 (0.00%)
After hours: 04:20PM EST
Full screen
Trade prices are not sourced from all markets
Previous close183.13
Open186.64
Bid185.00 x 800
Ask195.98 x 800
Day's range183.98 - 189.15
52-week range156.56 - 280.62
Volume186,803
Avg. volume209,796
Market cap20.366B
Beta (5Y monthly)0.63
PE ratio (TTM)N/A
EPS (TTM)-9.23
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est286.55
  • Zacks

    Wall Street Analysts Think BeiGene, Ltd. (BGNE) Could Surge 44.28%: Read This Before Placing a Bet

    The mean of analysts' price targets for BeiGene, Ltd. (BGNE) points to a 44.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

  • Business Wire

    BeiGene to Host ASH Investor Meeting in Person and via Webcast on December 10, 2023

    BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass., November 29, 2023--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced that it will host an Investor Event at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego and via webcast at 8:00 PM PST on December 10, 2023. This event will cover BeiGene’s R&D progress and broad hematology portfolio, with invited speakers presenting key data from the ASH 2023.

  • Business Wire

    BeiGene to Present New Data Highlighting Hematology Portfolio and Pipeline Strengths at ASH 2023

    BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass., November 28, 2023--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced the presentation of new data across a range of assets and blood cancers at the upcoming 65th American Society of Hematology (ASH) Annual Meeting and Exposition, taking place December 9-12 in San Diego, California. BeiGene has 24 abstracts accepted at ASH, with three abstracts scheduled for oral presentations.